about
A Salmonella typhi OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line.Correlation of the expression of YY1 and Fas cell surface death receptor with apoptosis of peripheral blood mononuclear cells, and the development of multiple organ dysfunction in children with sepsis.Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival.Death receptor 5 expression is inversely correlated with prostate cancer progression.Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis.P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.Inhibition of tumor progression during allergic airway inflammation in a murine model: significant role of TGF-β.HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: implications in allergic airway inflammation.The NO TRAIL to YES TRAIL in cancer therapy (review).Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases.Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis.Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies.Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1.[Corrigendum] Death receptor 5 expression is inversely correlated with prostate cancer progression.Sulforaphane induces differential modulation of mitochondrial biogenesis and dynamics in normal cells and tumor cells.A novel role of Yin-Yang-1 in pulmonary tuberculosis through the regulation of the chemokine CCL4.Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance.Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively.Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction.Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana.Role of CXCL13 in AsthmaCytotoxic effect caspase activation dependent of a genetically engineered fusion protein with a CD154 peptide mimetic (OmpC-CD154) on B-NHL cell lines is mediated by the inhibition of bcl-6 and YY1 through MAPK p38 activationA potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cellsRole of Yin Yang-1 (YY1) in the transcription regulation of the multi-drug resistance (MDR1) geneDual role of hypoxia-inducible factor 1 α in experimental pulmonary tuberculosis: its implication as a new therapeutic targetA Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity
P50
Q33193416-F7003FC9-508D-4F6C-855D-053515EFB0AFQ33670949-0E6CF843-FED9-48C4-9F60-64D46EB57C42Q33937454-E9FB2EEB-2C06-4438-84DC-937EF45315CFQ34426868-ACDED0AB-D579-4892-B8DF-1C4209FF7928Q35022295-DABA81BA-2CA2-4280-8CF1-6FF4300CF053Q35811165-A489B46C-A0C9-4C96-A2F6-A7BAD2A91607Q35967977-114E95A1-B7EB-4773-B026-15ECE5832870Q36226525-B83F0649-3030-49DD-8972-780A281AFE96Q36929447-A9B0AACE-59C8-4E45-BDE7-591383B3BC10Q37162743-2E5F3151-6BD1-421D-9D06-CABB2A00BA9EQ37262987-FBD4C4E2-80EB-4DDC-B11C-C6F0C7B2E648Q37976093-A2A87F1B-FECC-4440-A76C-282F6993505EQ38287545-CFFFA29D-23AC-474A-9A53-AEA956269589Q38604509-A7AF8C4A-E830-4BF4-A7AF-A545E2CECC04Q38725455-050919D0-260E-41F6-8412-02ADE2D9619CQ38801609-A4B18A8C-89BC-48A9-9BF1-F030C6A9E9C1Q38980604-F57B32CE-33A6-4E71-9CD0-4109FABE666AQ39782797-FC5F1CC0-DE57-4386-8653-742FBCB9DF10Q40174151-D8672E92-A0E3-4015-8D7D-94F2E31FBFAEQ40265695-2619AF37-8620-4293-A43F-A33FD745B487Q40388476-6C2101F3-9BC0-43DC-BC6A-F138EDD7252BQ40507932-767035C7-6B2C-479C-98B8-BC07AEAE01E0Q46074399-9614E81C-DB94-4DB3-A21E-C30864A91ACEQ46184588-549E5009-C993-461D-A540-5DB3B8090014Q46601400-63F1A191-E390-443A-A15C-1EB52560BFF4Q47773582-A1FD219C-4830-4FCA-AA15-FB9ABF78C0EFQ56978033-FEB2C17E-8106-48F9-9F7E-9128FEC09F14Q57048018-D429F69F-B9A3-48C9-9127-A98987203942Q82749262-EC84CDF9-3502-41E9-A6D5-B5A404544DADQ88262692-E08E0601-146F-4CC1-B02D-B65578A1CACCQ88921633-1ADCF09A-1C93-4198-9F97-4D19A337A84BQ92508057-C00C1159-5D45-4806-BA2A-C4C708383503
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mario I. Vega
@ast
Mario I. Vega
@en
Mario I. Vega
@es
Mario I. Vega
@nl
type
label
Mario I. Vega
@ast
Mario I. Vega
@en
Mario I. Vega
@es
Mario I. Vega
@nl
prefLabel
Mario I. Vega
@ast
Mario I. Vega
@en
Mario I. Vega
@es
Mario I. Vega
@nl
P108
P106
P108
P1153
7102943430
P31
P496
0000-0002-3932-2483